AstraZeneca Reports H1 2026 Growth, Reconfirms Full-Year Guidance

The Tip Desk · July 27, 2026 · 1 min read

Total revenue rose 6% at constant exchange rates, driven by Oncology and Rare Disease performance despite headwinds in China and the US.

AstraZeneca Plc reported that total revenue for the first half of 2026 increased by 6% at constant exchange rates (CER). Growth in the Rare Disease and Oncology sectors offset headwinds resulting from China volume-based procurement and the loss of exclusivity for Farxiga in the US. Core EPS and Core Operating profit both increased by 11%.

Financial results for H1 2026 show total revenue of $30,672 million compared to $28,045 million in H1 2025. The company's Core EPS was $5.21. Net debt increased by $3,538 million during the six months ending June 30, 2026, reaching $26,912 million. Net cash inflow from operating activities decreased by $875 million to $6,224 million, impacted by foreign exchange fluctuations, higher taxation paid, and working capital movements [5, 12, 15].

In July 2026, AstraZeneca entered an exclusive license agreement with Dizal Pharmaceutical Co for Zegfrovy, a lung cancer treatment. The deal includes a $600 million upfront payment and potential milestone payments of up to $900 million. Additionally, the company closed a strategic collaboration with CSPC Pharmaceuticals on April 14, 2026, involving an upfront payment of $1.2 billion.

Regarding shareholder returns, the interim dividend was increased by 3 cents to $1.06 per share. The company intends to increase the total annual dividend for FY 2026 to $3.30 per share.

AstraZeneca reconfirmed its FY 2026 guidance at CER, expecting Total Revenue to increase by a mid-to-high single-digit percentage and Core EPS to increase by a low double-digit percentage. The company also stated it remains on track to meet its ambition of $80 billion in Total Revenue by 2030.